Results mixed on Merck's new painkiller (AP)
13th Nov 2006, 20:24 GMT
AP - The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication's approval.
Results mixed on Merck's new painkiller (AP) related news:
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Merck: Arcoxia heart risk same as Voltaren — United Press International - Health Business
Latest news from Yahoo! News: Health News:
- Health care costs could jump 10 percent (AP)
- More South Africans get AIDS medicine (AP)
- Europe to draw up strategy against obesity (AFP)
- Clinical Trials Update: Nov. 13, 2006 (HealthDay)
- Pharmacy Program Helps Elderly Take Their Meds (HealthDay)
- Red meat may raise breast cancer risk (AP)
- Insurers' plan aims to cover uninsured (AP)
- FDA: Tamiflu patients need monitoring (AP)
- Flu Drug Tamiflu May Cause Odd Behavior in Children (HealthDay)
- Flu drug carries new warning after delirium reports (AFP)